Poly[N‐(2‐hydroxypropyl)methacrylamide]‐modified magnetic .gamma.‐F2O3 nanoparticles conjugated with doxorubicin for glioblastoma treatment

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61389013%3A_____%2F20%3A00519564" target="_blank" >RIV/61389013:_____/20:00519564 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/68378041:_____/20:00519564 RIV/61383082:_____/20:00000689 RIV/00216208:11110/20:10400428 RIV/00216208:11130/20:10400428

Výsledek na webu

<a href="https://chemistry-europe.onlinelibrary.wiley.com/doi/full/10.1002/cmdc.201900564" target="_blank" >https://chemistry-europe.onlinelibrary.wiley.com/doi/full/10.1002/cmdc.201900564</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1002/cmdc.201900564" target="_blank" >10.1002/cmdc.201900564</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Poly[N‐(2‐hydroxypropyl)methacrylamide]‐modified magnetic .gamma.‐F2O3 nanoparticles conjugated with doxorubicin for glioblastoma treatment

Popis výsledku v původním jazyce

With the aim to develop a new anticancer agent, we prepared poly[N‐(2‐hydroxypropyl)methacrylamide‐co‐methyl 2‐methacrylamidoacetate] [P(HP‐MMAA)], which was reacted with hydrazine to poly[N‐(2‐hydroxypropyl)methacrylamide‐co‐N‐(2‐hydrazinyl‐2‐oxoethyl)methacrylamide] [P(HP‐MAH)] to conjugate doxorubicin (Dox) via hydrazone bond. The resulting P(HP‐MAH)‐Dox conjugate was used as a coating of magnetic γ‐Fe2O3 nanoparticles obtained by the coprecipitation method. In vitro toxicity of various concentrations of Dox, P(HP‐MAH)‐Dox, and γ‐Fe2O3@P(HP‐MAH)‐Dox nanoparticles was determined on somatic healthy cells (human bone marrow stromal cells hMSC), human glioblastoma line (GaMG), and primary human glioblastoma (GBM) cells isolated from GBM patients both at a short and prolonged exposition time (up to 7 days). Due to hydrolysis of the hydrazone bond in acid milieu of tumor cells and Dox release, the γ‐Fe2O3@P(HP‐MAH)‐Dox nanoparticles significantly decreased the GaMG and GBM cell growth compared to free Dox and P(HP‐MAH)‐Dox in low concentration (10 nM), whereas in hMSCs it remained without effect. γ‐F2O3@PHP nanoparticles alone did not affect the viability of any of the tested cells.

Název v anglickém jazyce

Poly[N‐(2‐hydroxypropyl)methacrylamide]‐modified magnetic .gamma.‐F2O3 nanoparticles conjugated with doxorubicin for glioblastoma treatment

Popis výsledku anglicky

With the aim to develop a new anticancer agent, we prepared poly[N‐(2‐hydroxypropyl)methacrylamide‐co‐methyl 2‐methacrylamidoacetate] [P(HP‐MMAA)], which was reacted with hydrazine to poly[N‐(2‐hydroxypropyl)methacrylamide‐co‐N‐(2‐hydrazinyl‐2‐oxoethyl)methacrylamide] [P(HP‐MAH)] to conjugate doxorubicin (Dox) via hydrazone bond. The resulting P(HP‐MAH)‐Dox conjugate was used as a coating of magnetic γ‐Fe2O3 nanoparticles obtained by the coprecipitation method. In vitro toxicity of various concentrations of Dox, P(HP‐MAH)‐Dox, and γ‐Fe2O3@P(HP‐MAH)‐Dox nanoparticles was determined on somatic healthy cells (human bone marrow stromal cells hMSC), human glioblastoma line (GaMG), and primary human glioblastoma (GBM) cells isolated from GBM patients both at a short and prolonged exposition time (up to 7 days). Due to hydrolysis of the hydrazone bond in acid milieu of tumor cells and Dox release, the γ‐Fe2O3@P(HP‐MAH)‐Dox nanoparticles significantly decreased the GaMG and GBM cell growth compared to free Dox and P(HP‐MAH)‐Dox in low concentration (10 nM), whereas in hMSCs it remained without effect. γ‐F2O3@PHP nanoparticles alone did not affect the viability of any of the tested cells.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

10404 - Polymer science

Projekt

<a href="/cs/project/GA17-04918S" target="_blank" >GA17-04918S: Léčba glioblastomu pomocí superparamagnetických nanočástic na bázi oxidů železa s povrchově konjugovaným léčivem</a><br>

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2020

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

ChemMedChem

ISSN

1860-7179

e-ISSN

—

Svazek periodika

15

Číslo periodika v rámci svazku

1

Stát vydavatele periodika

DE - Spolková republika Německo

Počet stran výsledku

9

Strana od-do

96-104

Kód UT WoS článku

000495798800001

EID výsledku v databázi Scopus

2-s2.0-85075201973